GPTHEALTH
Gpt Healthcare Limited
Each stock's 10,000-path forecast, rendered as light.
Gpt Healthcare Limited (GPTHEALTH) Stock Analysis & Case Study
Is GPTHEALTH a good buy? The data-driven verdict.
Gpt Healthcare Limited (GPTHEALTH) trades at ₹159,on the numbers it worth a closer look, a Downstox Snapshot Score of 58/100.
On the numbers, Gpt Healthcare Limited (GPTHEALTH) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 31.4× earnings, ROE of 28.5%, a 54% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
GPTHEALTH fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How GPTHEALTH ranks against the 2,373 companies in our screener
- GPTHEALTH's market cap of 1,308 Cr ranks in the 44th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GPTHEALTH's book value of ₹2 ranks in the bottom 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GPTHEALTH's promoter holding of 65.6% ranks in the 64th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GPTHEALTH's 3-year profit (PAT) growth of 18.0% ranks in the 54th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GPTHEALTH's debt-to-equity ratio of 0.61x is lower than 29% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
We do not hold a 3-year revenue growth figure for GPTHEALTH, as of 9 Aug 2026, so it is not ranked here.
Is GPTHEALTH overvalued? GPTHEALTH P/E vs peers
GPTHEALTH trades at 31.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
GPTHEALTH share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.4y of GPTHEALTH history (-10%/yr drift, 33%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GPTHEALTH 2027 | ₹108 | ₹164 | ₹250 | +3% |
| GPTHEALTH 2028 | ₹93 | ₹169 | ₹308 | +6% |
| GPTHEALTH 2029 | ₹85 | ₹174 | ₹360 | +9% |
| GPTHEALTH 2030 | ₹77 | ₹180 | ₹419 | +13% |
| GPTHEALTH 2031 | ₹72 | ₹185 | ₹474 | +16% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GPTHEALTH goes up, or doubles?
The bull case for GPTHEALTH
- GPTHEALTH's return on equity of 28.5% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GPTHEALTH's return on capital employed of 23.7% ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹360.
The bear case & risks
- GPTHEALTH's P/E of 31.4x is lower than 44% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 101.3× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹85.
GPTHEALTH volatility & expected range, how bumpy is the ride?
Over the last 2.4 years GPTHEALTH compounded at -10%/year with annualized volatility of 33%. That volatility implies a 1-year 80% range of ₹108-₹250, the honest backbone behind any single price target.
GPTHEALTH price forecast, the full 60-month probability fan
GPTHEALTH price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GPTHEALTH hits common targets within the simulated horizon?
Full multi-horizon detail on the GPTHEALTH price target & forecast page.
GPTHEALTH Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. GPTHEALTH scores 5/8, mixed financial health.
GPTHEALTH MTF margin & leverage across 9 brokers
Margin Trading Facility lets you buy GPTHEALTH with part of the capital. Lower margin % = higher leverage. Rates compared across 9 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Zerodha | 29.62% | 3.4× |
| Groww | 29.61% | 3.4× |
| Dhan | 40.00% | 2.5× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 30.11% | 3.3× |
| PocketfulCHEAPEST | 29.49% | 3.4× |
| Fyers | 50.00% | 2.0× |
| Anand Rathi | 29.62% | 3.4× |
| Share India | 29.61% | 3.4× |
Compare every broker on the GPTHEALTH MTF page.
About Gpt Healthcare Limited: sector, index & market-cap context
Gpt Healthcare Limited (GPTHEALTH) is a small-cap NSE-listed company, with a market capitalisation of ₹1,308 Cr. See more stocks on our screener.
How the GPTHEALTH Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Gpt Healthcare Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GPTHEALTH analysis, FAQs
Is Gpt Healthcare Limited (GPTHEALTH) a good buy?
On the numbers, Gpt Healthcare Limited (GPTHEALTH) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 31.4× earnings, ROE of 28.5%, a 54% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GPTHEALTH overvalued or undervalued?
GPTHEALTH trades at 31.4× earnings, premium versus the ~22× long-run Nifty average.
What is the GPTHEALTH share price target for 2031?
GPTHEALTH's probability-weighted 2031 median target is ₹185, with an 80% range of ₹72-₹474 (10,000-path Monte-Carlo).
What is the probability GPTHEALTH doubles in 5 years?
The modelled probability of GPTHEALTH reaching ₹319 (2×) within 5 years is 23%.
What is the bull case for GPTHEALTH?
GPTHEALTH's return on equity of 28.5% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. GPTHEALTH's return on capital employed of 23.7% ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in GPTHEALTH?
GPTHEALTH's P/E of 31.4x is lower than 44% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 101.3× price-to-book means most of the value is intangible/expectations, not assets on the books.